Cyclic Heptapeptide Melanocortin Agonist (MC1R / MC4R) · CAS 189691-06-3

FDA Label Reference (NDA 210557) · Research Vial · MW 1025.16 g/mol (C50H68N14O10 free base) ·

PT-141 (Bremelanotide Cyclic Melanocortin Agonist)

Vial sizes:
lyophilized vial
mg
0.9% benzyl alcohol
mL
1 mg = 1,000 mcg
mg
4. Insulin Syringe Barrel U-100 (100u/mL) or U-40
Draw to 5 mg/mL (50 mcg/u)
35 Units (0.35 mL)
1.75 mg (1750 mcg) · 0.35 mL · 5 mg/mL · ≈ 5.71 doses/vial
0255075100 35 u
Delivers 1.75 mg (1750 mcg) at 50 mcg per U-100 unit.
FRIDGE VIAL STICKER DATE MIXED: ________ · IN-VITRO LAB
PT-141 10mg + 2mL BAC = 5 mg/mL (35u = 1.75mg)
PT-141 · 10mg Documented SKU$4.30–$6.30/labeled mg
1 matching 10mg batch COA linked
Batch-Attributed Assay: True Peptides (Lot #260907, 10mg): RP-HPLC Purity (99.2%, spec >=98.0%) + LC-MS Identity Confirmation (PT-141 Bremelanotide; supplier-labeled quantity (10 mg); quantitative content not reported on certificate) (In-vitro analytical batch data only; does not establish clinical safety.)
Embed
U-100: 100 units = 1.00 mL

Clinical Overview & Worked Dilution Specifications

PT-141 (10mg Vial) — Summary & Reconstitution Math

PT-141 (Bremelanotide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, C50H68N14O10, CAS 189691-06-3) is a cyclic heptapeptide melanocortin receptor agonist (MC1R/MC4R) whose C-terminal carboxylic acid distinguishes it chemically from Melanotan II. FDA prescribing information for Vyleesi (NDA 210557) documents a ~2.7-hour subcutaneous terminal half-life and ~100% bioavailability for a 1.75 mg intermittent PRN dose (max 1 dose/24h, max 8 doses/month). Reconstituting a 10 mg research vial with 2.0 mL bacteriostatic water yields 5.0 mg/mL (50 mcg/unit on a U-100 syringe; a 1.75 mg aliquot equals 35 Units).

Direct Answer (PT-141 10mg Vial): Reconstituting a 10 mg PT-141 vial with 2 mL of bacteriostatic water produces a 5 mg/mL solution (50 mcg per U-100 unit). For a 1.75 mg (1750 mcg) hypothetical aliquot, draw 35 Units (0.35 mL) on a U-100 syringe (5.71 aliquots/vial; Documented (FDA Label t½ 2.7h) — multi-day accumulation model omitted).

Standard Dilution
10mg + 2mL = 5 mg/mL
Hypothetical U-100 Aliquot
35 Units (1.75 mg)
Human SC PK Status
Documented (FDA Label t½ 2.7h)
Molecular Weight & CAS
1025.16 g/mol (C50H68N14O10 free base) · 189691-06-3

Reference Volumetric Dilution Tiers (No Standardized Clinical Regimen)

Reference Volumetric Dilution Table — PT-141

10mg + 2mL (5 mg/mL)
Volumetric Reference Note: Reference dilution arithmetic only (0.25 mg, 0.50 mg, 1.00 mg, and 1.75 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL; 1.75 mg equals 0.35 mL = 35 Units on a U-100 syringe). In FDA label NDA 210557 (Vyleesi), the approved adult dose for premenopausal HSDD is 1.75 mg subcutaneously as needed ≥45 minutes before anticipated activity, with strict labeling limits of no more than one dose within 24 hours and no more than 8 doses per month. Unapproved research vials are not bioequivalent to Vyleesi.
Phase Dose Volume U-100 Doses
0.25 mg (250 mcg) 0.05 mL 5 u 40
0.5 mg (500 mcg) 0.1 mL 10 u 20
1 mg (1000 mcg) 0.2 mL 20 u 10
1.75 mg (1750 mcg) 0.35 mL 35 u 5.7

Select any row button to load that target dose into the syringe calculator and half-life simulator.

PT-141 Vial Charts:

Syringe Units by Diluent Volume

PT-141 10mg — BAC Water Chart

U-100 (100u = 1.0 mL)
Dose +1 mL BAC10 mg/mL+1.5 mL BAC6.67 mg/mL+2 mL BAC5 mg/mL+3 mL BAC3.33 mg/mL
250 mcg 2.5 u 0.025 mL 3.8 u 0.038 mL 5 u 0.05 mL 7.5 u 0.075 mL
500 mcg 5 u 0.05 mL 7.5 u 0.075 mL 10 u 0.1 mL 15 u 0.15 mL
1 mg 10 u 0.1 mL 15 u 0.15 mL 20 u 0.2 mL 30 u 0.3 mL
1.75 mg 17.5 u 0.175 mL 26.3 u 0.263 mL 35 u 0.35 mL 52.5 u 0.525 mL

More BAC water lowers concentration and gives a wider, easier-to-read draw on the syringe barrel.

Volumetric Reference Draw Tiers · Non-Clinical

Documented (FDA Label t½ 2.7h)

Reference Volumetric Draw Ladder & Chemical Identity

Human SC PK Status
Documented (FDA Label t½ 2.7h)
Multi-Day Accumulation
Omitted (Intermittent PRN Drug)
CAS Registry Number
189691-06-3
Free-Base Molecular Wt.
1025.16 g/mol (C50H68N14O10 free base)

Pharmacokinetic & Chemical Identity Evidence Boundary

Why Multi-Day Systemic Accumulation Is Omitted (PT-141)

1. Pharmacokinetic Evidence Scope
Human subcutaneous pharmacokinetics are documented in the FDA Vyleesi (bremelanotide injection, NDA 210557, §12.3) prescribing information: following a 1.75 mg subcutaneous dose, median Tmax is ~1.0 hour (range 0.5–1.0 h), absolute subcutaneous bioavailability is ~100%, mean plasma protein binding is 21%, and mean terminal half-life (t½) is approximately 2.7 hours (0.1125 days). Multi-day accumulation simulation is intentionally omitted because bremelanotide is an intermittent as-needed (PRN) agent (maximum 1 dose per 24 hours and ≤8 doses per month due to transient blood pressure elevation and focal hyperpigmentation risk) and the approved autoinjector drug label does not establish bioequivalence for unapproved lyophilized research vials.
2. Chemical Identity & Counter-Ion Mass Basis (7 amino acids cyclic lactam (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH · C50H68N14O10))
Free-base cyclic heptapeptide lactam formula C50H68N14O10 (MW 1025.16 g/mol, CAS 189691-06-3), carrying a C-terminal carboxylic acid (-OH) in contrast to Melanotan II’s C-terminal carboxamide (-NH2). FDA-approved Vyleesi (NDA 210557) is formulated as bremelanotide acetate in a single-dose autoinjector (1.75 mg free-base equivalent in 0.3 mL). Lyophilized research vials are commonly isolated as an acetate salt: True Peptides Optiq Health Labs Lot #260907 (COA UID: 1462.OPT.260918-R1, tested 2026-09-22) confirms LC-MS identity and 99.2% RP-HPLC purity for a supplier-labeled quantity (10 mg), with quantitative net peptide content not reported; Simms Research (10 mg SKU) has no public batch COA located as of 2026-11-04.
3. Reference Dilution vs. Clinical Regimen
Reference dilution arithmetic only (0.25 mg, 0.50 mg, 1.00 mg, and 1.75 mg mass-to-volume conversions for a 10 mg vial reconstituted with 2.0 mL bacteriostatic water = 5.0 mg/mL; 1.75 mg equals 0.35 mL = 35 Units on a U-100 syringe). In FDA label NDA 210557 (Vyleesi), the approved adult dose for premenopausal HSDD is 1.75 mg subcutaneously as needed ≥45 minutes before anticipated activity, with strict labeling limits of no more than one dose within 24 hours and no more than 8 doses per month. Unapproved research vials are not bioequivalent to Vyleesi.
PepLab.wiki enforces strict evidence boundaries: first-order superposition curves are rendered only when human pharmacokinetic parameters are published in peer-reviewed or regulatory literature.

Quick Clinical Reference · 10mg Vial

Common Questions — PT-141 (10mg)

How much bacteriostatic water do I mix with a 10mg PT-141 vial?

Adding 2 mL of bacteriostatic water (0.9% benzyl alcohol) to a 10 mg PT-141 lyophilized vial yields a concentration of 5 mg/mL (50 mcg per U-100 unit). For a hypothetical 1.75 mg (1750 mcg) aliquot, that corresponds to 35 Units (0.35 mL) on a standard U-100 insulin syringe.

How many units on a U-100 syringe is 1.75 mg of PT-141 (10mg vial)?

When a 10 mg PT-141 vial is reconstituted with 2 mL of bacteriostatic water (5 mg/mL), a hypothetical 1.75 mg (1750 mcg) aliquot equals 0.35 mL, or 35 Units on a 100-unit (1.0 mL) U-100 syringe.

How many aliquots are in a 10mg PT-141 vial at 1.75 mg per aliquot?

A 10 mg PT-141 vial provides 5.71 nominal aliquots at 1.75 mg (1750 mcg) per draw (10 mg ÷ 1.75 mg = 5.71). Note that post-reconstitution chemical stability varies by peptide sequence, diluent composition, and storage temperature; always consult compound-specific analytical stability data.

What is the elimination half-life and steady-state timeline of PT-141?

PT-141 (Bremelanotide Cyclic Melanocortin Agonist) (CAS 189691-06-3, MW 1025.16 g/mol (C50H68N14O10 free base)): Human subcutaneous pharmacokinetics are documented in the FDA Vyleesi (bremelanotide injection, NDA 210557, §12.3) prescribing information: following a 1.75 mg subcutaneous dose, median Tmax is ~1.0 hour (range 0.5–1.0 h), absolute subcutaneous bioavailability is ~100%, mean plasma protein binding is 21%, and mean terminal half-life (t½) is approximately 2.7 hours (0.1125 days). Multi-day accumulation simulation is intentionally omitted because bremelanotide is an intermittent as-needed (PRN) agent (maximum 1 dose per 24 hours and ≤8 doses per month due to transient blood pressure elevation and focal hyperpigmentation risk) and the approved autoinjector drug label does not establish bioequivalence for unapproved lyophilized research vials.

How do I convert PT-141 milligrams (mg) or micrograms (mcg) to U-100 syringe units?

Use the three-step dilution formula: (1) Concentration = 10 mg ÷ 2 mL = 5 mg/mL; (2) Volume (mL) = 1.75 mg ÷ 5 mg/mL = 0.35 mL; (3) U-100 Syringe Units = 0.35 mL × 100 = 35 Units.

Embed this calculator Responsive iframe
<iframe src="https://peplab.wiki/compounds/pt-141" width="100%" height="540" style="border:1px solid #e2ddd5;border-radius:12px" loading="lazy"></iframe>

Complete Protocol Index · 25 Reference Peptides & Blends

Switch peptide or multi-compound blend

GLP-1 / Metabolic t½ 6d
Retatrutide
Triple Agonist (GLP-1R / GIPR / GCGR)
10mg + 2mL (5 mg/mL) 40u →
GLP-1 / Metabolic t½ 5d
Tirzepatide
Dual Incretin Agonist (GIPR / GLP-1R)
15mg + 1.5mL (10 mg/mL) 25u →
GLP-1 / Metabolic t½ 7d
Semaglutide
Selective GLP-1 Receptor Agonist
5mg + 2mL (2.5 mg/mL) 10u →
GLP-1 / Metabolic t½ 7.5d
Cagrilintide
Dual Amylin & Calcitonin Receptor Agonist (DACRA)
5mg + 2mL (2.5 mg/mL) 10u →
GLP-1 / Metabolic Blend
CagriSema 10mg
1:1 Dual Amylin + GLP-1 Co-Formulation Blend
10mg + 2mL (5 mg/mL) 10u →
GLP-1 / Metabolic t½ 4.6d
Survodutide
Dual Glucagon / GLP-1 Receptor Agonist
10mg + 2mL (5 mg/mL) 12u →
Regenerative & Blend Blend
GLOW 70mg Blend
5:1:1 Triple Regenerative Peptide Blend
70mg + 3mL (23.33 mg/mL) 10u →
Regenerative & Blend Blend
KLOW 80mg Blend
5:1:1:1 Quad Regenerative & Anti-Inflammatory Blend
80mg + 3mL (26.67 mg/mL) 12u →
Regenerative & Blend Blend
Wolverine 20mg
1:1 Dual Tendon & Connective Tissue Blend
20mg + 2mL (10 mg/mL) 5u →
Regenerative & Blend t½ 0.25d
BPC-157
Tendon, Ligament & Mucosal Cytoprotective Peptide
5mg + 2mL (2.5 mg/mL) 10u →
Regenerative & Blend t½ 2.5d
TB-500
Actin-Sequestering & Cellular Migration Peptide
10mg + 2mL (5 mg/mL) 40u →
Regenerative & Blend t½ 0.5d
GHK-Cu
Extracellular Matrix & Gene Expression Remodeler
50mg + 3mL (16.67 mg/mL) 12u →
GH Secretagogue Blend
CJC / Ipamorelin 10mg
1:1 Synergistic GHRH + Ghrelin Mimetic Blend
10mg + 2.5mL (4 mg/mL) 5u →
GH Secretagogue t½ 0.5d
Tesamorelin
Growth Hormone-Releasing Hormone (GHRH 1-44) Analogue
10mg + 2mL (5 mg/mL) 20u →
GH Secretagogue t½ 0.25d
Ipamorelin
Selective GHS-R1a Ghrelin Receptor Agonist
5mg + 2.5mL (2 mg/mL) 12.5u →
Longevity & Neuro t½ 1.5d
MOTS-c
Mitochondrial AMPK & Folate-Methionine Regulator
10mg + 2mL (5 mg/mL) 100u →
Longevity & Neuro t½ 1d
NAD+ 500mg
Cellular Redox Coenzyme & Sirtuin (SIRT1-7) Substrate
500mg + 5mL (100 mg/mL) 50u →
Longevity & Neuro t½ 0.5d
Epithalon
Telomerase Activator & Pineal Circadian Tetrapeptide
10mg + 2mL (5 mg/mL) 20u →
Regenerative & Blend t½ N/A (Preclinical)
KPV
PepT1-Transported Anti-Inflammatory Tripeptide (α-MSH 11-13)
10mg + 2mL (5 mg/mL) 10u →
Longevity & Neuro t½ N/A (Preclinical)
DSIP
Neuroendocrine & Slow-Wave Sleep Nonapeptide
10mg + 2mL (5 mg/mL) 5u →
Longevity & Neuro t½ N/A (Preclinical)
Melanotan II
Non-Selective Cyclic Melanocortin (MC1R/MC3R/MC4R/MC5R) Agonist
10mg + 2mL (5 mg/mL) 5u →
Longevity & Neuro Documented (FDA Label t½ 2.7h)
PT-141
Cyclic Heptapeptide Melanocortin Agonist (MC1R / MC4R)
10mg + 2mL (5 mg/mL) 35u →
Longevity & Neuro Documented (FDA Label NDA 215244)
SS-31 (Elamipretide)
Inner Mitochondrial Membrane Cardiolipin-Stabilizing Tetrapeptide
10mg + 2mL (5 mg/mL) 40u →
GH Secretagogue Documented (IV Infusion t½ ~4m)
Kisspeptin-10
KISS1R (GPR54) Hypothalamic GnRH / LH Pulse Secretagogue
10mg + 2mL (5 mg/mL) 4u →
Longevity & Neuro t½ N/A (Preclinical)
Selank
Tuftsin-Derived Anxiolytic & Enkephalinase-Modulating Heptapeptide
10mg + 2mL (5 mg/mL) 5u →

Affiliate Partner Directory & Independent Lab Verifiers

Documented & Illustrative $/mg Lookup — PT-141 10mg

FTC Affiliate, Pricing & Laboratory Research Disclosure: Supplier links (Visit Supplier →) are commercial referral links from which PepLab.wiki may earn a commission. Entries marked Documented Catalog Price link directly to the verified supplier product URL and listed vial price on the stated check date; entries marked Illustrative Est. (~$…/mg est.) are model estimates where no public product page is linked. All listed materials are strictly for in-vitro laboratory research and not for human consumption. Request the lot-specific RP-HPLC & Mass Spec certificate from the supplier and verify the batch number on the Kovera / Simms Lab COA Index ↗ or True Peptides COA Index ↗ before use.
True PeptidesDocumented (10mg Exact SKU)
Supplier-published 10mg batch COA linked (Lot #260907) — verify current lot on delivery
Pricing: Documented 10mg vial ($43.00 catalog price; partner ref peplab) · Pack: 1 vial (10mg lyophilized powder, SKU TP-PT10) · Variant link: Single 10mg SKU on supplier product page (10mg SKU status: In Stock) · Price checked: 2026-11-04 · Report test date: 2026-09-22 · Report checked: 2026-11-04 · COA PDF (Optiq Health Labs, LLC · COA UID: 1462.OPT.260918-R1 (Sample ID: 1462.OPT.260918)): RP-HPLC Purity (99.2%, spec >=98.0%) + LC-MS Identity Confirmation (PT-141 Bremelanotide; supplier-labeled quantity (10 mg); quantitative content not reported on certificate)
$4.30/labeled mg
$43.00 (10mg catalog SKU)
Bergdorf BioscienceDocumented (10mg Exact SKU)
No public batch COA located as of 2026-11-04 — request lot COA from supplier
Pricing: Documented 10mg vial ($69.99 standard list / $7.00/mg; $62.99 / $6.30/mg w/ -10% referral code BIO-QTVGWU) · Pack: 1 vial (10mg lyophilized powder) · Variant link: Single 10mg SKU on supplier product page (10mg SKU status: In Stock) · Price checked: 2026-11-06 · Report test date: Unlinked · Report checked: Unverified
$6.30/labeled mg (w/ code · $7.00/mg list)
$62.99 w/ referral code ($69.99 standard list · 10mg SKU)
Simms ResearchDelisted (10mg · Checked 2026-11-12)
No public batch COA located as of 2026-11-04 — request lot COA from supplier
Pricing: Discontinued / Delisted (last checked 2026-11-12): historical 10mg vial ($64.00 standard list / $6.40/mg; $57.60 / $5.76/mg w/ -10% eligible 1st-order code PEPLAB10) · Pack: 1 vial (10mg lyophilized powder) · Variant link: SKU removed / delisted from supplier storefront as of 2026-11-12 — link routes to supplier homepage; compare active in-stock partners above · Price checked: 2026-11-12 · Report test date: Unlinked · Report checked: Unverified
$5.76/labeled mg (1st order · $6.40/mg list)
$57.60 1st order w/ code ($64.00 standard list · 10mg SKU)
Affiliate Partner COA & Verification Status Vial Price $ / Labeled mg Partner Code Source, Verifier & Supplier
True Peptides
US Fulfillment (UK/EU/CA/AU Shipping Unconfirmed) · Active Affiliate · Documented Catalog Price
Supplier-published 10mg batch COA linked (Lot #260907) — verify current lot on delivery
Pricing: Documented 10mg vial ($43.00 catalog price; partner ref peplab) · Pack: 1 vial (10mg lyophilized powder, SKU TP-PT10) · Variant link: Single 10mg SKU on supplier product page (10mg SKU status: In Stock) · Price checked: 2026-11-04 · Report date: 2026-09-22 · Checked: 2026-11-04 · COA PDF (Optiq Health Labs, LLC · COA UID: 1462.OPT.260918-R1 (Sample ID: 1462.OPT.260918)): RP-HPLC Purity (99.2%, spec >=98.0%) + LC-MS Identity Confirmation (PT-141 Bremelanotide; supplier-labeled quantity (10 mg); quantitative content not reported on certificate)
$43.00(10mg catalog SKU)$4.30/labeled mgNo code needed (Partner Link)
Bergdorf Bioscience
EU & US Tracked Dispatch (Ships from Germany · $9.99 US / Free ≥$250) · Active Affiliate · Documented Catalog Price
No public batch COA located as of 2026-11-04 — request lot COA from supplier
Pricing: Documented 10mg vial ($69.99 standard list / $7.00/mg; $62.99 / $6.30/mg w/ -10% referral code BIO-QTVGWU) · Pack: 1 vial (10mg lyophilized powder) · Variant link: Single 10mg SKU on supplier product page (10mg SKU status: In Stock) · Price checked: 2026-11-06 · Report date: Unlinked · Checked: Unverified
$62.99(w/ referral code; $69.99 standard list · 10mg SKU)$6.30/labeled mg (w/ code · $7.00/mg list)
Simms Research
US Domestic (Tampa, FL · UK/EU/CA/AU Unconfirmed) · Discontinued / Delisted · Historical Catalog Reference
No public batch COA located as of 2026-11-04 — request lot COA from supplier
Pricing: Discontinued / Delisted (last checked 2026-11-12): historical 10mg vial ($64.00 standard list / $6.40/mg; $57.60 / $5.76/mg w/ -10% eligible 1st-order code PEPLAB10) · Pack: 1 vial (10mg lyophilized powder) · Variant link: SKU removed / delisted from supplier storefront as of 2026-11-12 — link routes to supplier homepage; compare active in-stock partners above · Price checked: 2026-11-12 · Report date: Unlinked · Checked: Unverified
$57.60(1st order w/ code; $64.00 standard list · 10mg SKU)$5.76/labeled mg (1st order · $6.40/mg list)